Sarepta Therapeutics, Inc. (0L35.L) LSE
16.33
-0.33(-1.98%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Sarepta Therapeutics, Inc.
Address
215 First Street
Cambridge, MA 02142
United States of America (the)
Phone
617 274 4000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
1372
First IPO Date
January 29, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Douglas S. Ingram | Chief Executive Officer & Director | 1.84M | 1963 |
| Joseph Bratica | Controller & Vice President | 438,513 | 1964 |
| Ryan H. Wong | Executive Vice President & Chief Financial Officer | 633,899 | 1979 |
| Cristin L. Rothfuss | Executive Vice President, General Counsel & Company Secretary | 806,778 | 1968 |
| Ian Michael Estepan | President & Chief Operating Officer | 1.02M | 1976 |
| Louise R. Rodino-Klapac | President of Research & Development and Technical Operations | 1.03M | 1978 |
| Tamara Thornton | Director of Finance, Treasury & Investor Relations | 0 | N/A |
| Rachael Potter | Chief Scientific Officer | 0 | N/A |
| Patrick Moss | Executive Vice President & Chief Commercial Officer | 0 | N/A |
| Diane L. Berry | Executive Vice President and Chief of Global Policy & Advocacy Officer | 0 | N/A |
| James Richardson | Executive VP & Chief Medical Officer | 0 | N/A |
| Mary Jenkins | Senior Manager of Investor Relations | 0 | N/A |
| Alison Nasisi | Executive Vice President & Chief People Officer | 0 | N/A |
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
